Thomas Hesterkamp
In his role as Head of the Translational Project Management Office of HZI/DZIF Thomas is supporting academic product development projects through stages of lead optimization, candidate nomination, preclinical development into early exploratory clinical development. Thomas was involved in the early clinical development of rVSV-ZEBOV (V920, now Ervebo®, MSD) and MVA-MERS-S vaccines and is the acting DZIF contract lead in the CEPI-funded clinical development and stockpiling of MVA-MERS-S to prevent the Middle East Respiratory Syndrome. Thomas is the designated CEO of the antibacterial company Myxobiotics that is driving the optimization and early development of the cystobactamid broad-spectrum anti-bacterial. Thomas has >20 years business experience also from previous roles in industry. Thomas is a trained human biologist.
This presentation to the AMR community is part of our ongoing road-show to present Myxobiotics as an anti-bacterial investment case. Myxobiotics is developing the cystobactamid broad-spectrum anti-bacterial for treatment of cUTI and possibly HAP/VAP.